Goldfinch Bio CEO Tony Johnson (L) and Karuna Therapeutics CEO Bill Meury
Karuna licenses Goldfinch assets to compete with Boehringer Ingelheim in neuroscience
Karuna Therapeutics is looking to compete with Boehringer Ingelheim on depression and anxiety with a new license to Goldfinch Bio’s assets …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
